We begin our research endeavors with a solid foundation for study design and methodology. We have conducted systematic reviews of the current state of computerized assessments, led focus groups with primary care physicians to learn about their confidence and methods for diagnosing brain disorders, and reviewed qualitative results from feasibility studies in primary care settings.
We believe all novel assessments should be backed with evidence-based support before being used in clinical care. We have performed several types of validation with our tasks with sensitivity and specificity analyses, concurrent validity analyses, neuroanatomical validity analyses, and validation in several language adaptations across the globe.
Studies aimed at discovering links between TabCAT and biomarkers play a crucial role in early detection and diagnosis, treatment monitoring over time, and predicting change over time. We have seen significant associations between our tests and Aβ-PET and tau-PET status, and continue to perform research in this exciting field.
We believe in health equity for all, and the need for accessible tools is growing. We continue to validate our tools in multiple language adaptations, examine social determinants of health, and explore neurocognitive disorders in underserved populations such as those experiencing homelessness.
The TabCAT-BHA Cognitive Score, a summary metric of memory, executive, and language tests, is accurate for detecting cognitive impairment in English- and Spanish-speaking older adults and is sensitive to earliest cognitive changes related to Alzheimer’s disease.
The TabCAT Match and Flanker tasks are feasible and reliable tests for at-home testing of executive functions in older adults at-risk for cognitive decline, even among those without prior technology experience
Performance on the TabCAT-BHA subtests is associated with microstructural changes in white matter of the brain in clinically normal and cognitively impaired older adults.
The TabCAT-BHA is an efficient, validated assessment for the detection of mild cognitive impairment and dementia due to Alzheimer’s and other neurodegenerative diseases.